Service de soins palliatifs et de support, Département de médecine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Hospiz im Park, Klinik für Palliative Care.
Swiss Med Wkly. 2024 Feb 15;154:3590. doi: 10.57187/s.3590.
Palliative sedation is defined as the monitored use of medications intended to induce a state of decreased or absent awareness (unconsciousness) to relieve the burden of otherwise intractable suffering in a manner ethically acceptable to the patient, their family, and healthcare providers. In Switzerland, the prevalence of continuous deep sedation until death increased from 4.7% in 2001 to 17.5% of all deceased in 2013, depending on the research method used and on regional variations. Yet, these numbers may be overestimated due to a lack of understanding of the term "continuous deep sedation" by for example respondents of the questionnaire-based study. Inadequately trained and inexperienced healthcare professionals may incorrectly or inappropriately perform palliative sedation due to uncertainties regarding its definitions and practice. Therefore, the expert members of the Bigorio group and the authors of this manuscript believe that national recommendations should be published and made available to healthcare professionals to provide practical, terminological, and ethical guidance. The Bigorio group is the working group of the Swiss Palliative Care Society whose task is to publish clinical recommendations at a national level in Switzerland. These recommendations aim to provide guidance on the most critical questions and issues related to palliative sedation. The Swiss Society of Palliative Care (palliative.ch) mandated a writing board comprising four clinical experts (three physicians and one ethicist) and two national academic experts to revise the 2005 Bigorio guidelines. A first draft was created based on a narrative literature review, which was internally reviewed by five academic institutions (Lausanne, Geneva, Bern, Zürich, and Basel) and the heads of all working groups of the Swiss Society of Palliative Care before finalising the guidelines. The following themes are discussed regarding palliative sedation: (a) definitions and clinical aspects, (b) the decision-making process, (c) communication with patients and families, (d) patient monitoring, (e) pharmacological approaches, and (f) ethical and controversial issues. Palliative sedation must be practised with clinical and ethical accuracy and competence to avoid harm and ethically questionable use. Specialist palliative care teams should be consulted before initiating palliative sedation to avoid overlooking other potential treatment options for the patient's symptoms and suffering.
缓和性镇静是指在监测下使用药物,以诱导意识降低或消失(无意识)的状态,从而减轻患者、其家属和医疗保健提供者在伦理上可接受的方式下无法控制的痛苦。在瑞士,2001 年持续深度镇静直至死亡的比例为 4.7%,而到 2013 年,这一比例上升至所有死亡者的 17.5%,这取决于所使用的研究方法和区域差异。然而,由于例如问卷调查研究的受访者对“持续深度镇静”一词缺乏理解,这些数字可能被高估了。由于对其定义和实践的不确定性,未经充分培训和缺乏经验的医疗保健专业人员可能会错误或不适当地进行缓和性镇静。因此,Bigorio 小组的专家成员和本文的作者认为,应该发布国家建议,并向医疗保健专业人员提供实用、术语和伦理指导。Bigorio 小组是瑞士姑息治疗学会的工作组,其任务是在瑞士全国范围内发布临床建议。这些建议旨在就与缓和性镇静相关的最关键问题和问题提供指导。瑞士姑息治疗学会(palliative.ch)委托一个由四名临床专家(三名医生和一名伦理学家)和两名国家学术专家组成的写作委员会来修订 2005 年的 Bigorio 指南。根据叙述性文献综述创建了一份初稿,该初稿由五所学术机构(洛桑、日内瓦、伯尔尼、苏黎世和巴塞尔)和瑞士姑息治疗学会所有工作组的负责人进行了内部审查,然后最终确定了指南。以下主题涉及缓和性镇静:(a)定义和临床方面,(b)决策过程,(c)与患者和家属的沟通,(d)患者监测,(e)药物治疗方法,和(f)伦理和有争议的问题。缓和性镇静必须以临床和伦理准确性和能力来实践,以避免伤害和在伦理上有问题的使用。在开始缓和性镇静之前,应咨询专业的姑息治疗团队,以避免忽视患者症状和痛苦的其他潜在治疗选择。